Hot Features
Premium
Level up your trading with our powerful tools and real-time insights all in one place.
Period:
Draw Mode:
| Volume | 52,902 |
|
|||||
| News | - | ||||||
| Day High | 19.35 | Low High |
|||||
| Day Low | 17.23 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| ArriVent BioPharma Inc | AVBP | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -1.00 | -5.40% | 17.51 | 17:56:42 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 18.46 | 17.23 | 19.35 | 17.51 | 18.51 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 1,163 | 52,902 | US$ 18.33 | US$ 969,691 | - | 14.35 - 25.5076 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 15:18:17 | 7 | US$ 17.51 | USD |
ArriVent BioPharma Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 558.6M | 31.96M | - | 0 | -69.33M | -2.17 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
ArriVent BioPharma News
| Date | Time | Source | News Article |
|---|---|---|---|
| 6/05/2024 | 06:15 | Edgar (US Regulatory) | Form 8-K - Current report |
| 6/05/2024 | 06:00 | GlobeNewswire Inc. | ArriVent Announces a Multi-Target ADC Collaboration with.. |
| 5/16/2024 | 15:11 | Edgar (US Regulatory) | Form 8-K - Current report |
| 5/16/2024 | 15:05 | GlobeNewswire Inc. | ArriVent Appoints John Hohneker, M.D., to its Board of.. |
| 5/08/2024 | 07:01 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 5/08/2024 | 07:00 | Edgar (US Regulatory) | Form 8-K - Current report |
| 5/08/2024 | 07:00 | GlobeNewswire Inc. | ArriVent BioPharma Reports First Quarter 2024 Financial.. |
| 4/22/2024 | 15:05 | GlobeNewswire Inc. | ArriVent Appoints Kristine Peterson to its Board of.. |
| 3/28/2024 | 15:05 | GlobeNewswire Inc. | ArriVent BioPharma Reports Full Year 2023 Financial Results |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AVBP Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 18.73 | 19.86 | 17.23 | 18.69 | 53,390 | -1.22 | -6.51% |
| 1 Month | 19.65 | 21.00 | 17.2075 | 19.00 | 46,450 | -2.14 | -10.89% |
| 3 Months | 17.08 | 21.00 | 14.35 | 17.38 | 89,948 | 0.43 | 2.52% |
| 6 Months | 24.00 | 25.5076 | 14.35 | 19.17 | 156,787 | -6.49 | -27.04% |
| 1 Year | 24.00 | 25.5076 | 14.35 | 19.17 | 156,787 | -6.49 | -27.04% |
| 3 Years | 24.00 | 25.5076 | 14.35 | 19.17 | 156,787 | -6.49 | -27.04% |
| 5 Years | 24.00 | 25.5076 | 14.35 | 19.17 | 156,787 | -6.49 | -27.04% |
ArriVent BioPharma Description
| ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. |
